The endocannabinoid system and its therapeutic exploitation
The DOI matches its Crossref record; 160 of the 161 references it cites were found in a registry or an index.
Abstract
The term 'endocannabinoid' - originally coined in the mid-1990s after the discovery of membrane receptors for the psychoactive principle in Cannabis, Delta9-tetrahydrocannabinol and their endogenous ligands - now indicates a whole signalling system that comprises cannabinoid receptors, endogenous ligands and enzymes for ligand biosynthesis and inactivation. This system seems to be involved in an ever-increasing number of pathological conditions. With novel products already being aimed at the pharmaceutical market little more than a decade since the discovery of cannabinoid receptors, the endocannabinoid system seems to hold even more promise for the future development of therapeutic drugs. We explore the conditions under which the potential of targeting the endocannabinoid system might be realized in the years to come.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The obvious implications are that cannabinoids and similarly acting drugs may regulate cognitive functions, modulate food intake, affect both female and male reproduction, provide neuroprotection and be involved in neurodegenerative diseases; pathophysiology of shock; inhibition of fertilized oocyte implantation; inhibition of cancer growth, angiogenesis and metastasis (for a review see ref. 71).”
From Paracetamol: New Vistas of an Old Drug (2006) · cites this paper as [71]
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 1×
“∆(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB1 receptor antagonist/inverse agonist SR 141716A Neuropsychopharmacology 24, 198–203 (2001).”
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011 · cited 1×
“The serendipitous cloning in 1990 of the first of such proteins, the CB 1 receptor, came from the screening of an 'orphan' G-protein-coupled receptor (GPCR) with several possible ligand”
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · cited 1×
“1 ), led to the identification of plasma membrane CANNABINOID RECEPTORS in 1988 (Ref”
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,393
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 1×
“Functions of the endocannabinoid system The components ( Figs 3 , 4 ) and possible physiological functions of the endocannabinoid system have been extensively reviewed in recent article”
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757
Research works printed but not linked: 4
- Mechoulam, R. in Cannabis as Therapeutic Agent (ed. Mechoulam, R.) 1–19 (CRC Press Roca Ranton, 1986). The most comprehensive history of the recreational and medicinal use of Cannabis throughout the centuries.
- Di Marzo, V., Bisogno, T., De Petrocellis, L., Berger, A. & Mechoulam, R. in Biology of Marijuana (ed. Onaivi, E.) 125–173 (Harwood Academic, Reading, 2002).
- Pertwee, R. G. in Cannabinoids (ed. Di Marzo, V.) 32–83 (Kluwer Academic, New York, 2004).
- Pop, E. Dexanabinol Pharmos. Curr. Opin. Investig. Drugs 1, 494–503 (2000).
Cited by
Items 801–900 of 1,001
Sermsaksasithorn, P., Nopsopon, T., Samuthpongtorn, C., Chotirosniramit, K., & Pongpirul, K. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1609667 · Cited by 6
“…the therapeutic potential of cannabis and its derivatives, particularly as their medical use becomes increasingly legalized in many countries, including Canada, Germany, Israel, and the Netherlands (Wilkinson et al., 2016; Schlag, 2020; Di Marzo et al., 2004;Paganoetal.,2022;Abuhasiraetal.,2018).”
Chen, B., Prabhu, A., Li, G., Kaltenbach, A. C., Wang, Y., Shakir, G., Natarelli, L., Megens, R. T. A., Jansen, Y. J. F. M., Ramanathan, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75214-2 · Cited by 6
Jaiswal, S., Gupta, G., & Ayyannan, S. R. (2022) · Archiv der Pharmazie · doi:10.1002/ardp.202200081 · Cited by 6
Formoterol dynamically alters endocannabinoid tone in the periaqueductal gray inducing headache
Peterson, I. L., Liktor‐Busa, E., Karlage, K. L., Young, S. J., Scholpa, N. E., Schnellmann, R. G., & Largent‐Milnes, T. M. (2024) · The Journal of Headache and Pain · doi:10.1186/s10194-024-01907-y · Cited by 6
Modulation of Pain by Endocannabinoids in the Periphery
Uhelski, M. L., Khasabova, I. A., & Simone, D. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.79673 · Cited by 6
Yun, C., Haleem, M. S., Jeong, S., Oyer, M. A., Driscoll, J. A., Chang, K. Y., Yun, J., Paul, J. T., Lubbe, R., Stock, S. R., et al. (2021) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.20.00573 · Cited by 6
Part I. Mechanisms of actions and metabolism of acetaminophen related to the neonatal brain
Angelis, D., Savani, R. C., Jagarapu, J., Hu, J., Wan-Huen, P., & Chalak, L. F. (2021) · Early Human Development · doi:10.1016/j.earlhumdev.2021.105406 · Cited by 6
Tavares, L. R. R., Petrilli, L. A., Baptista‐de‐Souza, D., Canto‐de‐Souza, L., Planeta, C. S., Guimarães, F. S., Nunes‐de‐Souza, R. L., & Canto‐de‐Souza, A. (2024) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0300 · Cited by 6
Role of the Endocannabinoid System in Alcoholic Liver Disease
Siegmund, S. (2010) · Digestive Diseases · doi:10.1159/000324283 · Cited by 6
Cannabinoids and the Urinary Bladder
Bakali, E. (2013) · Gynecology & Obstetrics · doi:10.4172/2161-0932.1000163 · Cited by 6
“The mechanism by which cannabinoid receptors could modulate this reflex is by the presence of CB1 receptors in the afferent nerve fibre endings located in the suburothelial layer, which is supported by in vitro studies where CB1 agonists reduce neuronal activity and attenuate bladder contractility as a result of elect…”
BackgroundNo more pain upon Gq‐protein‐coupled receptor activation: role of endocannabinoids
Hu, S. S., Ho, Y. ‐., & Chiou, L. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13231 · Cited by 6
Review: Pharmacological approaches to reduce adiposity
Day, C., & Bailey, C. J. (2006) · The British Journal of Diabetes · doi:10.1177/14746514060060030401 · Cited by 6
Metabolic syndrome: Demographic features, etiology, and clinical management
Wyne, K. L. (2005) · Current Atherosclerosis Reports · doi:10.1007/s11883-005-0051-z · Cited by 6
Ye, M., & Dawson, M. I. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.04.072 · Cited by 6
Sudano, I., Periat, D., & Noll, G. (2008) · Praxis · doi:10.1024/1661-8157.97.7.375 · Cited by 6
“Von dem pharmakologischen Verhalten und der Wirkung ist Anandamid dem D9-Tetrahydrocannabinol sehr ähnlich [1].”
BackgroundInfluentialHigh-Density Lipoprotein Cholesterol
Toth, P. P., & Gotto, A. M. (2006) · Fundamental and clinical cardiology · doi:10.3109/9781420019667.008 · Cited by 6
Pharmacological Prevention of Type 2 Diabetes
Scheen, A. J. (2008) · Wiley eBooks · doi:10.1002/9780470779750.ch29 · Cited by 6
“metabolism, both through central orexigenic effects and peripheral metabolic effects in adipose tissue, liver, skeletal muscle and pancreas [95,96].”
BackgroundAntezana, P. E., Municoy, S., Sofrás, F. M. S., Bellino, M. G., Evelson, P., & Desimone, M. F. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.125076 · Cited by 5
Tripathi, S. M., Sambhakar, S., Mishra, S. K., Malviya, R., & Sridhar, S. B. (2025) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2025.2522396 · Cited by 5
Neural Stem Cells and Cannabinoids in the Spotlight as Potential Therapy for Epilepsy
Lourenço, D. M., Ribeiro‐Rodrigues, L., Sebastião, A. M., Diógenes, M. J., & Xapelli, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197309 · Cited by 5
“…functions, such as the regulation of intestinal motility, fertility, circulatory system, myocardial function, myogenic, adipogenic, and osteo-and chondrogenic differentiations, metabolism, and inflammation [149–155]. endovanilloid system, in which AEA is known to act as a full agonist [146–148].”
Behera, S., Reddy, R. R., Taunk, K., Rapole, S., Pharande, R. R., & Suryawanshi, A. R. (2021) · Journal of Proteomics · doi:10.1016/j.jprot.2021.104463 · Cited by 5
Palmisano, M., Ramunno, C. F., Farhat, E., Dvir‐Ginzberg, M., Lutz, B., de Almodóvar, C. R., & Bilkei‐Gorzó, A. (2024) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2024.111954 · Cited by 5
“…levels, and extended longevity in mice, and GnRH administration countered the age-related neurogenesis decline (Zhang et al., 2013a), slowed down the ageing process in peripheral organs, increasing skin thickness, bones mass and reducing muscle weakness (Di Marzo et al., 2004; Tang and Cai, 2013).”
BackgroundPlescia, F., Plescia, F., Raffa, D., Cavallaro, A., Lavanco, G., Maggio, B., Raimondi, M. V., Daidone, G., Brancato, A., & Cannizzaro, C. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.06.004 · Cited by 5
Guzzo, L. S., Oliveira, C. C., Ferreira, R. C. M., Machado, D., Castor, M. G. M. E., Perez, A. C., Piscitelli, F., Marzo, V. D., Romero, T. R. L., & Duarte, I. D. G. (2021) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x2021e11071 · Cited by 5
“The levels of 2-AG, an endocannabinoid with equal efficacy at CB1 and CB2 receptors (26), were not increased in the presence of kahweol, which suggested that this mediator was not involved in kahweol antinociception.”
BackgroundInfluentialSelf-citationEmergence of Synthetic Cannabinoids as Drugs of Abuse
Joshi, N., & Sankhla, M. S. (2021) · Indian Journal of Forensic Medicine & Toxicology · doi:10.37506/ijfmt.v16i1.17422 · Cited by 5
Sphingosine kinase-dependent regulation of pro-resolving lipid mediators in Alzheimer's disease
Ayub, M., Jin, H. K., & Bae, J. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159126 · Cited by 5
Sloan, L. J., Funk, K. M., Tamiya, S., & Song, Z.-H. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.05.040 · Cited by 5
Rezende, B., Marques, K. L., de Carvalho, F. E. A., Gonçalves, V. M. D. S., de Oliveira, B. C. C. A., Nascimento, G. G., dos Santos, Y. B., Antunes, F., Barradas, P. C., Fontes-Dantas, F. L., et al. (2024) · Scientia Pharmaceutica · doi:10.3390/scipharm92030053 · Cited by 5
Updates in the General Approach to the Pediatric Poisoned Patient
Barrueto, F. F., Gattu, R. K., & Mazer-Amirshahi, M. E. (2013) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2013.06.002 · Cited by 5
Recent advances in the development of CB1R selective probes
Amenta, A., Caprioglio, D., Minassi, A., Panza, L., Passarella, D., Fasano, V., & Imperio, D. (2023) · Frontiers in Natural Products · doi:10.3389/fntpr.2023.1196321 · Cited by 5
Saipetch, C., Sachs, E., & Haneef, Z. (2016) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000000288 · Cited by 5
“The cannabinoid receptor was demonstrated in 1988.(21) THC is the psychoactive component,(21) while CBD may have anticonvulsive effects.”
Karimi, S. A., Noorbakhsh, M., Komaki, H., Nikoo, M. R., Hasanein, P., Shahidi, S., Faraji, N., & Komaki, A. (2021) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000638 · Cited by 5
“Ca2+ influx is a necessary step, both in neurotransmitter release and in the synthesis of endocannabinoids (Di Marzo et al., 2004).”
BackgroundVered, S., Beiser, A., Sulimani, L., Sznitman, S. R., Gonzales, M. M., Aparicio, H. J., DeCarli, C. S., Scott, M. R., Ghosh, S., Lewitus, G. M., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01301-x · Cited by 5
“The “clas-sic,” best-studied eCBs are 2-arachidonoyl (2-AG) and arachidonoyl ethanolamide (AEA), which bind directly to CB1 and CB2 receptors [2].”
BackgroundLOS ENDOCANNABINOIDES COMO UNA FUTURA HERRAMIENTA PARA EL TRATAMIENTO DE CÁNCER
Niño, F. M., & Torres-Vidales, G. (2014) · Revista Venezolana de Oncología · Cited by 5
Awumey, E. M., Howlett, A. C., & Diz, D. I. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00433.2005 · Cited by 5
“There exists a close correspondence in distribution of FAAH and CB1 receptors in the rat brain and their expression at the cellular level (7, 9).”
BackgroundInfluentialMarzo, V. D. (2006) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.2006.00770_3.x · Cited by 5
Self-citationLe syndrome metabolique: physiopathologie et traitement
Scheen, A. J. (2006) · ORBi (University of Liège) · Cited by 5
Novel pyrrolocycloalkylpyrazole analogues as CB1 ligands
Asproni, B., Manca, I., Pinna, G., Cichero, E., Fossa, P., Murineddu, G., Lazzari, P., Loriga, G., & Pinna, G. A. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13069 · Cited by 5
PET Imaging of the Endocannabinoid System
Terry, G. E., Raymont, V., & Horti, A. G. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_12 · Cited by 5
Endocannabinoids and their receptors as targets for treating metabolic and psychiatric disorders
Felder, C. C. (2006) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2006.10.015 · Cited by 5
Microbiota-driven gut-brain signaling underlies antidepressant effects of a GLP-1 analog
Bian, L., Cai, Y., Zhang, Y., Shen, L., Wang, H., Gao, F., Cai, N., Chen, W., You, C., Yang, Y., et al. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2026.05.003 · Cited by 4
Jia, X., Gao, S., Liu, X., Feng, Z., Wang, X. X., Lan, K., Lu, Y., Han, L., Wei, Y. B., & Liu, J. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02031-x · Cited by 4
Therapeutic potential of cannabinoids for treating atopic dermatitis
Stoco, A. A. G., & Mazzola, P. G. (2025) · Journal of Cannabis Research · doi:10.1186/s42238-025-00317-4 · Cited by 4
Il sistema endocannabinoide: attuali conoscenze e potenziali applicazioni in odontostomatologia
Pavanini, S., Lauriola, S., Mottola, A., & Cocchi, R. (2010) · Italian Oral Surgery · doi:10.1016/j.ios.2010.11.004 · Cited by 4
Cannabinoid receptor 2 signal promotes type 2 immunity in the lung
Liu, T., Liu, J., Chen, H., Zhou, X., Fu, W., Cao, Y., & Yang, J. H. (2023) · Cell Insight · doi:10.1016/j.cellin.2023.100124 · Cited by 4
“Accordingly, cannabinoids, either synthetic or from the natural source of cannabis, have been commonly utilized for therapeutic bene fi ts (Di Marzo, 2008; Di Marzo et al., 2004).”
BackgroundRegueras, E., Torres, L. M., & Velázquez, I. (2023) · Multidisciplinary Pain Journal · doi:10.20986/mpj.2023.1052/2023 · Cited by 4
N-Stearoylethanolamine Exerts Cardioprotective Effects in Old Rats
Kosiakova, H. V., Ah, B., Tm, H., Meged’, O. F., Klimashevsky, V., Matsokha, R., Tkachenko, O. S., Vs, A., Kvitnitskaya-Ryzhova, T., Lugovskyi, S. P., et al. (2024) · Current Aging Science · doi:10.2174/0118746098275323231226073348 · Cited by 4
Zhang, M., Tian, Q., & Liu, J. (2024) · Medical Principles and Practice · doi:10.1159/000540751 · Cited by 4
de Abreu, N. K., Feltrin, I. F., Pereira, D. M. R., Bezerra, P. P., & Aguiar, A. S. (2025) · HORMONES · doi:10.1007/s42000-025-00628-4 · Cited by 4
“The endocannabinoid system (ECS) has gained increasing attention in recent years for its role in regulating various physiological processes, such as energy balance, inflamma - tion, and muscle contractility [1, 2].”
Obesity: Increasing Awareness of Novel Environmental Factors
Niswender, K. D., & Beech, B. M. (2008) · Diabetes · doi:10.2337/db08-0527 · Cited by 4
“, targets the endocannabinoid system (12), which is closely allied to food reward, provides proof of principle of the complexity of the motivation for feeding in humans.”
BackgroundBlockade of the Endocannabinoid System for the Reduction of Cardiometabolic Risk Factors
Samaha, F. F., & Chou, C. M. (2008) · Obesity · doi:10.1038/oby.2008.476 · Cited by 4
“They have neuromodulatory actions in the sensory and autonomic nervous systems when stimulated by their endogenous ligands (14).”
BackgroundInfluentialTeixeira-Clerc, F., Julien, B., Grenard, P., Nhieu, J. T. V., Deveaux, V., Li, L., Serrière-Lanneau, V., Ledent, C. A., Mallat, A., & Lotersztajn, S. (2006) · médecine/sciences · doi:10.7202/013769ar · Cited by 4
Endocannabinoid system and its role in energy regulation
Matias, I., & Marzo, V. D. (2006) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.1.4.557 · Cited by 4
Self-citationCB2 receptor as a potential target in age-related diseases
Kauppinen, A., Nevalainen, T., Hytti, M., Salminen, A., & Parkkari, T. (2014) · Cited by 4
Forner-Piquer, I., Marzo, V. D., & Carnevali, O. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824464-7.00018-0 · Cited by 4
Self-citationTkacheva, O. N., Kashtanova, D. A., & Boytsov, S. A. (2015) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2015-6-83-86 · Cited by 4
“Чрезмерная ее активация ведет к нарушению толерантности к глюкозе, инсулинорезистентности, дислипидемии [28], а также к снижению синтеза белков “tight-junction” [29, 30].”
NEUROPLASTICIDADE – UMA ABORDAGEM TEÓRICA
Roque, B. S., Lukachewski, J. M., & Barbosa, C. P. (2016) · Revista Uningá · doi:10.46311/2318-0579.47.euj1262 · Cited by 4
Iannotti, F. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85131 · Cited by 4
“The term endocannabinoid system (ECS) was originally coined in the 1990s after the discovery of brain receptors, responsive to ∆9-tetrahydrocannabinol-THC (the primary psychoactive substance of Cannabis sativa) and the class of their endogenous ligands identified immediately thereafter [1].”
Lipid Signalling in Human Immune Response and Bone Remodelling under Microgravity
Fava, M., Leuti, A., & Maccarrone, M. (2020) · Applied Sciences · doi:10.3390/app10124309 · Cited by 4
“Endocannabinoids (ECs) are endogenous lipids that engage the same cell receptors targeted by the main psychoactive ingredient of Cannabis sativa and Cannabis indica, namely ∆9- tetrahydrocannabinol (THC) [74].”
BackgroundInfluentialTherapeutic Potential of Dronabinol: A Systematic Review of Human Trials
Lewandowska, J. A., Kapała, J. M., & Puchała, Ł. (2021) · Farmacja Polska · doi:10.32383/farmpol/142693 · Cited by 4
“Moreover, CB1Rs stimulation inhibits voltage-activated calcium channels and activates inwardly rectifying potassium channels [5].”
BackgroundNarrative Review: Phytocannabinoids and their Potential Use as a Phytochemotherapy
Panichayupakaranant, P. (2020) · International Journal of Pharmacognosy & Chinese Medicine · doi:10.23880/ipcm-16000209 · Cited by 4
Does cannabis hold the key to treating cardiometabolic disease?
Szmitko, P. E., & Verma, S. (2006) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0504 · Cited by 4
“The endocannabinoid system contributes to the regulation of food intake, energy balance, inflammation, and lipid and glucose metabolism, and might therefore play a fundamental role in the development of obesity and atherosclerosis”
BackgroundPrävention kardiovaskulärer Erkrankungen durch Blockade des Endocannabinoidsystems
Bramlage, P., Schindler, C., Thoenes, M., Bramlage, C. P., Böcking, W., & Kirch, W. (2007) · Herz · doi:10.1007/s00059-007-3021-0 · Cited by 4
“Die Blockade des körpereigenen Endocannabinoidsystems stellt einen neuen Ansatz zur Regulation des Körpergewichts sowie der Beeinflussung kardiometabolischer Risikofaktoren dar [6, 15].”
BackgroundNeto, A. S., Saheb, G. C. B., Arantes, B. S., Júnior, J. P., da Silva, R. B. S., & Buriti, N. A. (2008) · Arquivos Brasileiros de Ciências da Saúde · doi:10.7322/abcs.v33i1.176 · Cited by 4
High-Density Lipoprotein Cholesterol Therapies: THE NEXT FRONTIER IN LIPID MANAGEMENT
Duffy, D., & Rader, D. J. (2006) · Journal of Cardiopulmonary Rehabilitation · doi:10.1097/00008483-200601000-00001 · Cited by 4
Daley, E. (2019) · uO Research (University of Ottawa) · doi:10.20381/ruor-23054 · Cited by 4
“Select alkylamides can bind to the two receptors that are responsible for regulating pain and inflammation, among other physiological functions, mimicking the well-studied endocannabinoid ligand anandamide (Di Marzo et al., 2004; Urbatsch et al., 2000; Gertsch et al., 2010; Raduner et al., 2006).”
BackgroundRicci, V., Sarni, A., Berardis, D. D., Martinotti, G., & Maina, G. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251389574 · Cited by 3
“This complex lipid signaling system consists of cannabinoid receptors (primarily CB1 and CB2), endogenous ligands (endocannabinoids) such as anandamide (AEA) and 2-ara-chidonoylglycerol (2-AG), and enzymes responsible for their synthesis and degradation (Di Marzo et al., 2004).”
Structural insights into cannabinoid receptors CB1 and CB2: determinants of ligand selectivity
Varghese, A., Liu, J., Guo, W., Patterson, T. A., & Hong, H. (2026) · Frontiers in Chemical Biology · doi:10.3389/fchbi.2026.1830007 · Cited by 3
The role of cannabinoids in the management of symptoms in palliative care patients
Graczyk, M., & Leppert, W. (2021) · Palliative Medicine in Practice · doi:10.5603/pmpi.2021.0016 · Cited by 3
Neuro-Gastro-Cannabinology: A Novel Paradigm for Regulating Mood and Digestive Health
Turco, F., Brugnatelli, V., & Abalo, R. (2023) · Medical Cannabis and Cannabinoids · doi:10.1159/000534007 · Cited by 3
Gacso, Z., Adamson, G., Slama, J., Xie, C., Burdick, E., Persaud, K., Chowdhury, S., Ahmed, Z. S., Vaysman, E., Aminov, A., et al. (2024) · Neuroscience Letters · doi:10.1016/j.neulet.2024.138058 · Cited by 3
DeLong, G. T., Wolf, C. E., Poklis, A., & Lichtman, A. H. (2011) · Journal of Analytical Toxicology · doi:10.1093/anatox/35.7.496 · Cited by 3
Anorexia Nervosa and Cannabis Abuse: A Case Report
Karayilan, S., & Erol, A. (2013) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20121130090627 · Cited by 3
“THC and nabilone, which is an analogue of THC, are found to be effective in prevention of nausea and vomiting caused by cancer medications and their clinical use is recommended (8,9).”
BackgroundDrab, A., Haratym-Maj, A., Zagaja, M. P., Łuszczki, J. J., & Andres‐Mach, M. (2017) · Journal of Pre-Clinical and Clinical Research · doi:10.26444/jpccr/74636 · Cited by 3
Elisei, L., Moraes, T. R., Malta, I., Rodríguez, J. O., V, Marzo, V. D., & Galdino, G. (2023) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0291 · Cited by 3
“13 Both CB1R and CB2R belong to the class of G protein-coupled receptor (GPCR) family, whose activation modulates the adenylate cyclase and mitogen-activated protein kinase (MAPK) pathways through inhibitory G a i/o heterotrimeric G proteins, and which interact with b -arrestins.”
InfluentialSelf-citationAnticaries and Antigingivitis Properties of Cannabinoid-Containing Oral Health Products: A Review
Torabi, J., Luís, H., & Hurlbutt, M. (2024) · Cannabis and Cannabinoid Research · doi:10.1089/can.2023.0206 · Cited by 3
“22 The review analyzes existing evidence on CBDs’ anti-inflammatory and antibacterial effects for treating gingi-vitis.”
Lamberti, A., Serafini, M. T., Aprile, S., Bhela, I. P., Goutsiou, G., Pessolano, E., Fernandez-Ballester, G. J., Ferrer-Montiel, A. V., Martino, R. M. C. D., Fernández-Carvajal, A. M., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116845 · Cited by 3
Circulating Endocannabinoids and Cognitive Function in Older Adults
Vered, S., Beiser, A., Sulimani, L., Sznitman, S. R., Ghosh, S., Lewitus, G. M., Meiri, D., Seshadri, S. S., & Weinstein, G. (2024) · Aging and Disease · doi:10.14336/ad.2024.1427 · Cited by 3
Synthetic Cannabinoid Receptor Agonists (Spice) as New Recreational Psychoactive Substances
Helander, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800756-3.00101-0 · Cited by 3
Mogi, C., & Fukuyama, T. (2021) · Japanese Journal of Complementary and Alternative Medicine · doi:10.1625/jcam.18.37 · Cited by 3
Mechanismen der Schmerzentstehung: Schwerpunkt Peripherie
Konrad, C. J., & Schmelz, M. (2005) · Der Internist · doi:10.1007/s00108-005-1476-8 · Cited by 3
Calcium-induced modulation of synaptic transmission
Bregestovski, P. D., & Хаспеков, Л. Г. (2007) · Biochemistry (Moscow) Supplement Series A Membrane and Cell Biology · doi:10.1134/s1990747807010035 · Cited by 3
Regulation of Bone Remodeling by Central and Peripheral Nervous Signals
Takeda, S., & Ducy, P. F. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00016-1 · Cited by 3
Endocannabinoid system in the brain...and elsewhere
Scheen, A. J., Seutin, V., & Van Gaal, L. F. (2008) · ORBi (University of Liège) · Cited by 3
Obesidad, insuficiencia cardíaca y rimonabant
Delmonte, J. A. (2007) · Insuficiencia cardíaca · Cited by 3
López-Jaramillo, P. A., Pradilla, L. P., Bracho, Y., & Silva, F. (2005) · Revista Colombiana de Cardiología · Cited by 3
Weight Control in Individuals With Diabetes
Bloomgarden, Z. T. (2006) · Diabetes Care · doi:10.2337/dc06-zb12 · Cited by 3
Tratamiento de la diabetes tipo 2: revisión de las opciones y prioridades terapéuticas actuales
Arroyo, J., Caixàs, A., & Pi‐Sunyer, F. X. (2007) · Medicina Clínica · doi:10.1157/13113289 · Cited by 3
Avances en el tratamiento de la diabetes mellitus tipo 2 y la enfermedad cardiovascular
Pi-Sunyer, X. (2008) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(08)73556-8 · Cited by 3
Effects of Anandamide on IL-11 Production through the TRPV1 of Human Periodontal Ligament Cells
HARUTA, C. (2012) · THE JOURNAL OF THE STOMATOLOGICAL SOCIETY JAPAN · doi:10.5357/koubyou.79.1_7 · Cited by 3
John, M. (2005) · CRC Press eBooks · doi:10.1201/9781420048957.ch16 · Cited by 3
Cannabinoid receptor 1 antagonism in hepatocellular carcinoma: killing two birds with one stone
Bifulco, M., & Ciaglia, E. (2015) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000337 · Cited by 3
Self-citationLe système cannabinoïde : perspectives thérapeutiques au cours des hépatopathies chroniques
Lotersztajn, S., Teixeira-Clerc, F., Hézode, C., Nhieu, J. T. V., Deveaux, V., & Mallat, A. (2007) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(07)89369-9 · Cited by 3
“Les fonctions des autres ligands de CB1 et CB2 identifiés restent à ce jour indéterminées [1, 8].”
BackgroundEnergy Homeostasis: Endocannabinoid System
Marsicano, G., Pagotto, U., Cervino, C., & Pasquali, R. (2009) · Elsevier eBooks · doi:10.1016/b978-008045046-9.00459-9 · Cited by 3
Orexin receptors as therapeutic targets for addiction and anxiety disorders
Heros, F. D. L. (2016) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) · Cited by 3
Age-related changes in the phenotype of microglia
Imraish, A. (2018) · Nottingham ePrints (University of Nottingham) · Cited by 3
Callén, L. (2012) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · Cited by 3
Etude du mécanisme antalgique du Paracétamol ; région cérébrale et mécanisme mis en jeu.
Dalmann, R. (2015) · theses.fr (ABES) · doi:10.70675/f4f0f78bz6b88z470az9b81z39db132f662f · Cited by 3
Astrocytic Abnormalities in Schizophrenia
Saleki, K., Banazadeh, M., Abadi, B., Pirmoradi, Z., Esmaili, Z., Amiri, S., Pourahmad, R., Kohlmeier, K. A., & Shabani, M. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106618 · Cited by 2
Elias, A., Rosado, C., & Costa, M. D. C. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e40827 · Cited by 2
Metadata
- Authors
- Marzo, V. D., Bifulco, M., & Petrocellis, L. D.
- Affiliations
- Istituto di Chimica Biomolecolare (IT)
- Institute of Applied Science and Intelligent Systems (IT)
- University of Salerno (IT)
- Corresponding author
- Marzo, Vincenzo Di
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-09-01
- Volume
- 3
- Issue
- 9
- Pages
- 771-784
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2087674201
- Cited by
- 1,090
- References
- 161
- Citations by year
- 2026: 25 · 2025: 38 · 2024: 61 · 2023: 48 · 2022: 43 · 2021: 44 · 2020: 49 · 2019: 43 · 2018: 35 · 2017: 41 · 2016: 28 · 2015: 42 · 2014: 38 · 2013: 48 · 2012: 42
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- endocannabinoid system, cannabinoid receptors, cannabinoid therapeutics, drug development, pathological conditions
- MeSH terms
- Animals, Cannabinoids, Cannabis, Clinical Trials as Topic, Enzymes, Humans, Drug Design, Signal Transduction, Receptors, Cannabinoid, Cannabinoid Receptor Modulators, Cannabinoid Receptor Agonists, Cannabinoid Receptor Antagonists, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.